[Aim of CT]

Assess the anti-neovascularization activity of intravitreal bevacizumab, as determined by regression of neovascular vessels of retinopathy of prematurity (ROP), in neonates with acute stage 3 ROP in zone I or posterior zone II with plus disease.

[Recruitment criteria]

Birth weight ≤ 1500 grams

Gestational age ≤ 30 weeks

Diagnosis = stage 3 ROP in zone I or posterior zone II

Drug use = bevacizumab (Avastin®)

Without congenital systemic anomaly

Without congenital ocular abnormality.